E-Learning Center
Join Our Network
OncoFacts

Follow Imedex on Twitter

Register for an upcoming conference!

Phone: +1 (678) 242 0906
registration@imedex.com

6th International Congress on Myeloproliferative Diseases and Myelodysplastic Syndromes


Send Info

6th International Congress on Myeloproliferative Diseases and Myelodysplastic Syndromes

November 3-4, 2011

New York, NY

 

Continuing Medical Education
ACCME

Imedex®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex, LLC designates this live educational activity for a maximum of 13 AMA PRA Category 1 Credit™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Who Should Attend
This educational activity is specifically designed for hematologists, internists, oncologists and other physicians, physicians-in-training, and healthcare professionals (nurses, pharmacists) interested and/or involved in the care of patients with myeloproliferative diseases and myelodysplastic syndromes.

Objectives
After completion of this educational activity, participants should be able to:

  • Review the classification and pathogenesis of myelodysplastic diseases
  • Discuss current best practices in the treatment of MDS
  • Comment on novel drugs in MDS, with a focus on management of iron overload
  • Review new prognostic classifications and their relevance to allogeneic transplantation in primary myelofibrosis
  • Discuss novel markers and therapies beyond JAK2 in myelofi brosis
  • Review important genetic abnormalities in myeloproliferative disorders
  • Comment on the clinical significance of mutations in polycythemia vera
  • Identify the importance of cerebral circulation in outcomes related to polycythemia vera
  • Discuss molecular drug targets in myeloproliferative disorders
  • Review risk factors for thrombosis in MPDs
  • Review the most current updates in the biology and pathogenesis of CML
  • Improve response monitoring and overcome drug resistance to improve CML outcomes
  • Review the management of CML in pregnancy
  • Discuss second and third generation tyrosine kinase inhibitors and their current and future positioning within the current treatment armamentarium
  • Review treatment of accelerated and blast phase CML disease
  • Debate the optimal role of transplantation in CML

Tiziano Barbui, MD
Ospedali Riuniti di Bergamo
Bergamo, Italy

John M. Bennett, MD
University of Rochester Medical Center
Rochester, New York

Stefan Constantinescu, MD, PhD
Ludwig Institute for Cancer Research
Brussels, Belgium

Jorge Cortes, MD
The University of Texas
M. D. Anderson Cancer Center
Houston, Texas

Nick C.P. Cross, PhD, FRCPath
University of Southampton
Salisbury, United Kingdom

Michael Deininger, MD
University of Utah Health
Sciences Center
Salt Lake City, Utah

Pearlie K. Epling-Burnett, PharmD, PhD
H. Lee Moffi tt Cancer Center
and Research Institute
Tampa, Florida

Sergio A. Giralt, MD
Memorial Sloan-Kettering
Cancer Center
New York, New York

John Goldman, MD, FRCP
Hammersmith Hospital
Imperial College London
London, United Kingdom

Anthony R. Green, PhD, FRCP, FRCPath
Cambridge Institute for
Medical Research
Addenbrooke’s Hospital
Cambridge, United Kingdom

Rudiger Hehlmann, MD, PhD
Klinikum Mannheim der Universität
Mannheim, Germany

Ronald Hoffman, MD
Mount Sinai School of Medicine
New York, New York

Hagop M. Kantarjian, MD
The University of Texas
M. D. Anderson Cancer Center
Houston, Texas

Jean-Jacques Kiladjian, MD, PhD
Saint-Louis Hospital and
Paris 7 University
Paris, France

Heather A. Leitch, MD, PhD, FRCPC
St. Paul’s Hospital
University of British Columbia
Vancouver, BC, Canada

Ross Levine, MD
Memorial-Sloan Kettering Cancer Center
New York, NY

Alan F. List, MD
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida

Ruben A. Mesa, MD
Mayo Clinic
Scottsdale, Arizona

Tariq Mughal, MD, FRCP
University of Colorado Health Sciences Center
Denver, Colorado

Vesna Najfeld, MD
Mount Sinai School of Medicine
New York, New York

Heike L. Pahl, PhD
University Hospital Freiburg
Freiburg, Germany

Josef T. Prchal, MD
University of Utah Health
Sciences Center
Salt Lake City, Utah

Gail J. Roboz, MD
Weill Cornell Medical College
New York, New York

Andrew Schafer, MD
Weill Cornell Medical College
New York, New York

Richard T. Silver, MD, FACP
Weill Cornell Medical College
NewYork-Presbyterian Hospital/
Weill Cornell Medical Center

Radek Skoda, MD
University Hospital Basel
Basel, Switzerland

Jerry L. Spivak, MD, FACP
Johns Hopkins University
School of Medicine
Baltimore, Maryland

Alessandro M. Vannucchi, MD
University of Florence
Florence, Italy

Srdan Verstovsek, MD, PhD
The University of Texas
M. D. Anderson Cancer Center
Houston, Texas

Thursday, November 3, 2011

8:00 am
Pre-activity audience polling via ARS
Richard T. Silver, MD, FACP

Session I: Myelodysplastic Syndromes
Chairs: John M. Bennett, MD, and
Alan F. List, MD

8:20 am
Program overview
John M. Bennett, MD, and Alan F. List, MD

8:25 am
New molecular targets in MDS and MPN
Nicholas C.P. Cross, MA, PHD, FRCPath

8:50 am
Risk-adaptive strategies for MDS management
John M. Bennett, MD

9:15 am
The 5q syndrome: Molecular targets of disease and therapy
Alan F. List, MD

9:40 am
Immune signature-guided immunodepletion therapy in MDS
Pearlie K. Epling-Burnett, PharmD, PhD

10:05 am
Coffee break

10:25 am
Positioning hypomethylating agents and "the pipeline ahead"
Gail J. Roboz, MD

10:50 am
Progress in replacing the stem cell: Allogeneic HSCT
Sergio A. Giralt, MD

11:15 am
Lunch

Session II: Chronic Myeloid Leukemia
Chairs: John Goldman, MD, FRCP and
Rudiger Hehlmann, MD, PhD

1:05 pm
Update on the biology of CML
John Goldman, MD, FRCP

1:35 pm
Current treatment of CML with imatinib, dasatinib, and nilotinib
Hagop M. Kantarjian, MD

2:05 pm
New drugs in the treatment of CML
Jorge Cortes, MD

2:35 pm
How should patients be monitored? Current usage of FISH, PCR, mutation analysis, and plasma OCT-1
Michael Deininger, MD

3:05 pm
Coffee break

3:25 pm
Current management of accelerated- and blast-phase disease
Rudiger Hehlmann, MD, PhD

4:00 pm
Current status of bone marrow transplantation in CML
Sergio A. Giralt, MD

4:30 pm
Abstract presentations and discussion
Vesna Najfeld, PhD,
Jerry L. Spivak, MD, FACP, and
Ruben A. Mesa, MD

Chromosomal and FISH study of 286 patients with primary myelofibrosis reveals cryptic abnormalities and identifies lesions associated with favorable prognosis and disease progression
V. Najfeld, et al, P-1

Leukocyte plugging and microthrombi in capillaries contribute to decreased brain blood flow in animal models of myeloproliferative neoplasms
T. Santisakultarm, et al, P-2

Incidence, risk factors for early hepatotoxicity and its impact on survival in patients with myelofibrosis undergoing allogeneic hematopoietic cell transplantation
K. Wong, et al, P-3

5:15 pm
Closing notes and post-activity ARS assessment

5:30 pm
Adjourn

Friday, November 4, 2011

8:15 am
Welcome and pre-activity ARS assessment

Session III: Myeloproliferative Neoplasms
Chairs: Jerry L. Spivak, MD, FACP and
Andrew Schafer, MD

8:30 am
Clonal evolution and the MPN stem cell hierarchy
Radek Skoda, MD

9:00 am
JAK/STAT signalling and the MPN phenotype
Anthony R. Green, PhD, FRCP, FRCPath

9:30 am
Targeting JAK2 V617F and the signaling pathways synergizing with it
Stefan Constantinescu, MD, PhD

10:00 am
Coffee break

10:15 am
The molecular basis of polycythemia vera
Jerry L. Spivak, MD, FACP

10:45 am
Secondary erythrocytosis
Josef T. Prchal, MD

11:15 am
Using novel MPN biomarkers wisely: Strategies for diagnosis and clinical trials
Heike L. Pahl, PhD

11:45 am
Drugs for polycythemia vera therapy in 2011: Balancing benefits and risks
Jean-Jacques Kiladjian, MD, PhD

12:15 pm
Lunch

Session IV: Myeloproliferative Neoplasms cont’d
Chairs: Richard T. Silver, MD, FACP and
Ross Levine, MD

1:15 pm
Therapeutic targets for reducing the thrombosis rate in the MPN
Tiziano Barbui, MD

1:45 pm
Clinical correlates of MPN mutations
Alessandro M. Vannucchi, MD

2:15 pm
The potential of drug combinations in MPN treatment
Ronald Hoffman, MD

2:45 pm
Update on the treatment of myeloproliferative diseases with current JAK2 inhibitors
Srdan Verstovsek, MD, PhD

3:15 pm
Coffee break

3:30 pm
Assessing symptoms and response in MPN patients – Lessons from current and future therapies
Ruben A. Mesa, MD

4:00 pm
Anemia responses in myelofibrosis: Role of IMiD's and other therapies
Animesh Pardanani, MBBS, PhD

4:30 pm
Treatment of early myelofibrosis with interferon alpha-2b
Richard T. Silver, MD, FACP

5:00 pm
Closing notes and post-activity ARS assessment

5:30 pm
Adjourn

Abstract Submission Deadline extended until August 25, 2011.

 

Call for Abstracts

Participants interested in presenting data should submit abstracts online by August 25, 2011.

Abstracts are subject to acceptance by the Scientific Committee. Once accepted, abstracts will be published in the final course book and scheduled for oral or poster presentation.

Acceptance notifications and guidelines for poster presentations will be sent by September 15, 2011. Authors of accepted abstracts who have not registered will have until October 21, 2011 to do so at the rate of $325. After this date, abstracts without registered presenters will be disregarded.

Abstract Guidelines

  • Follow the online instructions
  • Abstracts must be written in English
  • Accepted format: Word document format, 9 point Arial font, 500 word count limit
  • Use a concise title
  • List affi liations of author(s) as briefl y as possible, with city, state and country
  • Place an asterisk (*) before the name of the presenting author
  • Use standard and well-accepted abbreviations
  • When using references, use standard and well-accepted formats
  • Abstract content should be single-spaced, typed in lower case and contain:
    • Purpose of the study
    • Summarized description of the project
    • Results and conclusions

Submission Deadline Extended: August 25, 2011

abstract

Discounted
If payment received by September 1, 2011

$325.00

Regular
If payment received by October 27, 2011

$425.00

Full/Onsite
If payment received after October 27, 2011

$525.00

Group discount (physicians only)*
*cannot be combined with any other discounts

-$50.00

Nurses/Residents/Students*
*proof of eligibility must accompany registration
*cannot be combined with any other discounts

$199.00

To Register: You may register online by October 27, 2011 at www.imedex.com, by calling Imedex at +1 (678) 242 0906 or by returning the registration form in this program by mail or fax to +1 (678) 242 0920. If you mail the form, please keep a copy for your records. Registration confi rmations will be issued before the meeting.

To qualify for special registration fees, registration and full payment must be received by Imedex by the dates specified.

Group Discounts: Each one of multiple registrants from the same institute or practice each receive a $50 discount off the published registration fees, provided all registration forms and payments are received together. Only one discount will apply per physician. Discounts are not available to Nurses/Residents/Students.

Payment: To pre-register, registration and payment must be received no later than October 27, 2011. Please register onsite after this date. Contact Imedex at +1 (678) 242 0906 or visit our website at www.imedex.com to ensure the course is being held as scheduled and to confi rm that the meeting is not full. Registration fees must be remitted by credit card or check. Checks should be payable to Imedex. Attendee is not registered until full payment is received.

Registration Fee Inclusions: Registration fees include admittance to all scientific sessions, conference materials, processing of certificates of attendance or continuing medical education, and all event functions as specifi ed in the agenda.

Cancellation: For registration fees to be refunded, written notice of cancellation must be received at meetings@imedex.com no later than October 27, 2011. The amount of registration fees remitted, minus a $75 administrative charge, will be refunded after the Congress. Substitutions are accepted with written notification. No refunds will be made if notice is received after October 27, 2011.

Imedex does not accept responsibility for covering travel, accommodation or any other costs incurred by registrants in the rare event that this program should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The event agenda is subject to change without notice.

New York Marriott at the Brooklyn Bridge
333 Adams Street
Brooklyn, New York 11201, USA
Tel.: +1 (718) 246 7000
Fax: +1 (718) 246 0563
www.brooklynmarriott.com

Located in New York City’s most celebrated neighborhood, just across the river from Manhattan sits the New York Marriott at the Brooklyn Bridge. Fresh from a 2007 expansion and renovation, the hotel boasts a relaxed but modern atmosphere with stateof- the-art amenities. The hotel sits within Renaissance Plaza, adjacent to the Metro Tech Center and surrounding universities and is a short 5 minutes from Manhattan and the Financial District, with 9 major subway lines all within one block.

For the convenience of attendees, a limited number of rooms have been reserved until October 12, 2011 at a discounted rate of $299 single/double occupancy, plus tax (currently at 14.75%) and an occupancy tax of $3.50 per night. This limited number of discounted rooms will be available until October 12, 2011. This discounted rate is not guaranteed outside the conference dates. Reservations received after October 12, 2011 or after the room block has been fi lled (whichever comes fi rst) are subject to availability and prevailing hotel rates.

To reserve your room please contact the New York Marriott at the Brooklyn Bridge reservations department at +1 (888) 436 3759 or +1 (718) 246 7000. To receive the group rate, callers must identify themselves as being with the International Congress on Myeloproliferative Diseases and Myelodysplastic Syndromes. Reservation requests received after October 12, 2011 may not be guaranteed the group rate.

You may also make hotel reservations online. Please use this link to access the hotels reservations system:
https://resweb.passkey.com/go/imedex

Dear Colleague,

It is our pleasure to invite you to join us at the 6th International Congress on Myeloproliferative Diseases and Myelodysplastic Syndromes. The 2011 Congress, which will be held November 3-4 at the New York Marriott at the Brooklyn Bridge, promises to be our most exciting and interactive meeting yet!

Since the inaugural Congress in 2001, this meeting has grown to nearly 600 attendees and has become the premier forum for discussion on the latest advances in myeloproliferative diseases and myelodysplastic syndromes. It allows attendees a forum to update their knowledge in the field, confirm their current practices and receive valuable take-home information on exciting new screening and staging modalities, management approaches and emerging treatment options.

Guided by the expertise of the leaders in the fi elds of molecular biology, pathology, immunology, and translational and clinical research, this Congress promises to be a stimulating, interactive forum for attendees from all relevant medical specialties. We will focus on the most recent updates and debates centered around polycythemia vera, essential thrombocythemia, myelofi brosis, chronic myeloid leukemia and myelodysplasia.

With its diverse mix of oncologists, hematologists, surgeons, and pathologists, this will be a great place to interact with your colleagues and learn from internationally renowned faculty.

We look forward to welcoming you in November to New York as the Fall brings its special beauty to this exciting international city!

Sincerely,

Richard T. Silver, MD, FACP
Chair and Convener

Jerry L. Spivak, MD, FACP
Co-Chair

Organizer

Imedex
11675 Rainwater Drive, Suite 600
Alpharetta, GA 30009, USA
Tel.: +1 (770) 751 7332
Fax: +1 (770) 751 7334
Email: meetings@imedex.com
Web: www.imedex.com

Download PDF Announcement

Chair and Convener:
Richard T. Silver, MD, FACP
Weill Cornell Medical College
NewYork-Presbyterian Hospital/
Weill Cornell Medical Center

Co-Chair:
Jerry L. Spivak, MD, FACP
Johns Hopkins University
School of Medicine
Baltimore, Maryland

Endorsed by:

Aplastic Anemia & MDS International Foundation

MDS Foundation

NewYork-Presbyterian

The following companies have provided an educational grant in support of this Congress:

SILVER

Bristol-Myers Squib

 

BRONZE

Celgene

 

 

Several options are available to companies interested in supporting this conference.
For more information, please contact Imedex at +1 (770) 751 7332, or by email at cme@imedex.com.

Untangling the Controversy:
Impact and Management of Iron Overload in MDS

November 3, 2011 - New York, New York
11:15 am – 1:05 pm
New York Marriott at the Brooklyn Bridge
Salon F-I

Myeloproliferative Neoplasms: The challenges, successes and strategies for 2012
November 3, 2011 - New York, New York
5:30 pm – 8:30 pm
Marriott Brooklyn Bridge
Salon A-D

The following companies are exhibitors at this Congress:

Celgen

Incyte

Novartis Oncology

 

Opportunities are available to companies interested in exhibiting at this conference.
For more information, please contact Cori Gunter at +1 (678) 242 0712, or by email at c.gunter@imedex.com.